 BEDMER, N.J.--BUSINESS WIRE--Tyme Technologies, Inc. Nasdaq:TYME the Company or TYME, an emerging biotechnology company developing cancer metabolism-based therapies CMBTsTM, today reported its conclusions from its recently conducted comprehensive strategic review and its fourth quarter and fiscal year 2021 financial results. Following my appointment as CEO of TYME, I assembled a group of independent key opinion leaders and industry experts alongside our internal team and launche 